Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer

Authors:
  • PGPetra van der Groep
    Petra van der Groep
  • ABAlwin Bouter
    Alwin Bouter
  • RZRichard van der Zanden
    Richard van der Zanden
  • FMFred H. Menko
    Fred H. Menko
  • HBHorst Buerger
    Horst Buerger
  • RVRene H.M. Verheijen
    Rene H.M. Verheijen
  • EWElsken van der Wall
    Elsken van der Wall
  • PJPaul J.
    Paul J.

Abstract
Foulkes et al. (1) reported that the expression of cytokeratin 5/6, indicating a basal epithelial phenotype, was statistically significantly associated with germline BRCA1 mutations in estrogen receptor (ER)- and erbB2-negative invasive breast cancers. It has recently been shown that the epidermal growth factor receptor (EGFR) is often expressed in basal-type (“stem”) cells of the breast (2), extending the phenotype of basal cells to ER−/erbB2−/EGFR+ breast cells. We examined the expression of EGFR by immunohistochemistry in the invasive breast cancers from 21 proven carriers of BRCA1 germline mutations and five proven carriers of BRCA2 germline mutations, as well as from a control group of 430 invasive breast cancers from patients unselected for a family history of breast cancer. Only clear membrane staining for EGFR was considered as overexpression. Of the 21 BRCA1-related breast cancers, 14 (67%) showed EGFR overexpression, 19 (90%) were ER negative, and 17 (81%) were erbB2 negative. Eleven (52%) of 21 tumors were ER−/erbB2−/EGFR+.